Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CDK12 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

FoundationOne® CDx (110)

FoundationOne® CDx (110)

CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CDK12 mutation	Ovarian Cancer	CDK12 mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
CDK12 mutation	HER2 Negative Breast Cancer	CDK12 mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	rucaparib Resistant: C3 – Early Trials rucaparib Resistant : C3	rucaparib Resistant: C3 – Early Trials rucaparib Resistant : C3
CDK12 mutation	Breast Cancer	CDK12 mutation	Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	GnRH stimulant Resistant: C3 – Early Trials GnRH stimulant Resistant : C3	GnRH stimulant Resistant: C3 – Early Trials GnRH stimulant Resistant : C3
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials enzalutamide + abiraterone acetate Resistant : C3	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials enzalutamide + abiraterone acetate Resistant : C3
CDK12 mutation	Ovarian Cancer	CDK12 mutation	Ovarian Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
CDK12 mutation	Non Small Cell Lung Cancer	CDK12 mutation	Non Small Cell Lung Cancer	olaparib Sensitive: C4 – Case Studies olaparib Sensitive : C4	olaparib Sensitive: C4 – Case Studies olaparib Sensitive : C4
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4